Last reviewed · How we verify
Single oral dose of cobicistat
Single oral dose of cobicistat is a Small molecule drug developed by Medicines for Malaria Venture. It is currently in Phase 1 development.
At a glance
| Generic name | Single oral dose of cobicistat |
|---|---|
| Sponsor | Medicines for Malaria Venture |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Participants. (PHASE1)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children (PHASE2, PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- A Study to Evaluate the Pharmacokinetics (PK) of Darunavir (DRV) and Cobicistat (COBI) After a Single Oral Administration of Darunavir/Cobicistat Fixed-Dose Combination in Healthy Japanese Adult Participants (PHASE4)
- A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care (PHASE3)
- A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants (PHASE1)
- A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Under Fed Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Single oral dose of cobicistat CI brief — competitive landscape report
- Single oral dose of cobicistat updates RSS · CI watch RSS
- Medicines for Malaria Venture portfolio CI
Frequently asked questions about Single oral dose of cobicistat
What is Single oral dose of cobicistat?
Single oral dose of cobicistat is a Small molecule drug developed by Medicines for Malaria Venture.
Who makes Single oral dose of cobicistat?
Single oral dose of cobicistat is developed by Medicines for Malaria Venture (see full Medicines for Malaria Venture pipeline at /company/medicines-for-malaria-venture).
What development phase is Single oral dose of cobicistat in?
Single oral dose of cobicistat is in Phase 1.